Clinical trials: Idarubicin
Hepatocellular Carcinoma, Immunotherapy
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
This is a single-arm, multicenter, exploratory clinical study evaluating the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection (QL1706) and lenvatinib for perioperative treatment of resectable HCC…
- Conditions
- Hepatocellular Carcinoma, Immunotherapy, Preoperative, PD-1
- Trial name
- NCT07131501
- Testing
- Radical surgery, TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Acute Myeloid Leukemia
Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation
Randomized Phase-III, two-arm, open-label, multi-center study in adult patients with AML and NPM1 mutation. Before Amendment No.
- Trial name
- NCT00893399
- Testing
- Gemtuzumab Ozogamicin (Mylotarg), standard chemotherapy
- Where
- 60 sites in Austria, Germany
- Volunteers
- 600 people
- Sponsor
- University of Ulm
Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Ph^1^, Absent
Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
The cure rate for childhood acute lymphoblastic leukemia (ALL) has increased significantly in recent decades and expected cure rates now exceed 85%.
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Ph^1^, Absent, B-cell Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT01990807
- Testing
- Idarubicin(IDA)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Acute Myeloid Leukemia, Pediatric AML
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
This research study investigates the tolerability of substituting two cycles of chemotherapy into the standard pediatric acute myeloid leukemia (AML) chemotherapy treatment regimen for patients with newly diagnosed AML at…
- Trial name
- NCT07059975
- Testing
- Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Baylor College of Medicine
Leukemia
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00534469
- Testing
- aldesleukin, filgrastim, busulfan
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML induction and consolidation therapy.
- Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD)
- Trial name
- NCT02632708
- Testing
- AG-120, AG-221, cytarabine
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 153 people
- Sponsor
- Institut de Recherches Internationales Servier
Acute Myeloid Leukemia
Study of SA+X in the Treatment of Newly Diagnosed AML
This is a phase II, open-label, multi-center study evaluating the efficacy and safety of sonrotoclax (SA) in combination with azacitidine (AZA) plus individualized targeted or chemotherapeutic agents in adult participants with…
- Trial name
- NCT07548710
- Testing
- Anthracycline, Ivosidenib, Gilteritinib
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Ruijin Hospital
Acute Myeloid Leukemia, Induction Chemotherapy
Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients
The purpose of this study is to evaluate the safety and efficacy of DAC combined with HAAG regimen in the induction treatment of newly diagnosed AML patients younger than 60 years.
- Trial name
- NCT04087967
- Testing
- Decitabine plus HAAG regimen, Idarubicine plus Cytarabine regimen
- Where
- China
- Volunteers
- 162 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Monocytic Leukemia
Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia
This study is a multicenter, randomized, prospective Phase II clinical trial designed to compare the effectiveness of two treatment approaches for patients with acute monocytic leukemia.
- Trial name
- NCT07512700
- Testing
- CACAG+VEN, 3+7
- Where
- 3 sites in China
- Volunteers
- 204 people
- Sponsor
- Chinese PLA General Hospital
Acute Lymphoblastic Leukemia
Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)
The protocol objective is providing adequate treatment and based on broad consensus in elderly patients with Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT01366898
- Testing
- Dexamethasona, Idarubicine, ARA-C, Methotrexate
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
Acute Promyelocytic Leukemia
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
The goal of this clinical research study is to learn if the combination of arsenic trioxide (ATO) with ATRA and possibly idarubicin is effective in treating patients with newly-diagnosed APL.
- Trial name
- NCT00413166
- Testing
- All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), Idarubicin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma (HCC)
TACE for HCC by TANDEM and Idarubicin
DcBeads and lipiodol-transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using doxorubicin result in about 50% objective response rate at 6 months (Precision V study, Lammer et al.
- Trial name
- TANDEM-IDA (NCT03349957)
- Testing
- Transarterial chemoembolization using TANDEM and idarubicin
- Where
- France
- Volunteers
- 98 people
- Sponsor
- University Hospital, Montpellier
Acute Myeloid Leukemia
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
The trial is a randomized, open-label phase II study comparing CPX-351 vs conventional intensivechemotherapy in patients with newly diagnosed de novo AML and intermediate- or adverse-risk genetics
- Trial name
- ALFA2101 (NCT05260528)
- Testing
- Cytarabine and Idarubicin, CPX-315
- Where
- 35 sites in France
- Volunteers
- 248 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
The primary objective was to evaluate the effect of blinatumomab on overall survival when compared to standard of care (SOC) chemotherapy.
- Trial name
- NCT02013167
- Testing
- Blinatumomab, Standard of Care Chemotherapy
- Where
- 117 sites in United States, Australia and 19 more
- Volunteers
- 405 people
- Sponsor
- Amgen
Leukemia, Myelocytic, Acute
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.
- Trial name
- NCT00126321
- Testing
- cladribine
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bonn
Acute Myeloid Leukemia
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
This research study is studying a targeted therapy (a form of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells) as a possible treatment for…
- Trial name
- NCT02560025
- Testing
- Alisertib, Cytarabine, Idarubicin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Lung Cancer, Inoperable Disease
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
This trial is designed to investigate the safety, response rates and survival outcomes of patients with inoperable lung cancer by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through…
- Trial name
- NCT06483347
- Testing
- ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Acute Myeloid Leukemia
Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia
The prognosis of elderly patients with relapsed or refractory acute myeloid leukemia (AML) is grave. Because of their chronological age and/or the presence of multiple co-morbidities, treatment-related mortality in elderly…
- Trial name
- NCT01039363
- Testing
- Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Samsung Medical Center
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
- Trial name
- NCT02626338
- Testing
- Crenolanib, Mitoxantrone, Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Newly Diagnosed Acute Myeloid Leukemia With High Risk
HVA vs IA/DA or VA in the Treatment of ND HR-AML
The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed…
- Trial name
- NCT06810791
- Testing
- HVA, VA, Standard Chemotherapy
- Where
- China
- Volunteers
- 876 people
- Sponsor
- Nanfang Hospital, Southern Medical University